Autopsy report · NCT00768339
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Cause of deathSlow enrollment
“Slow recruitment”
Life of this trial
- Ran for about 3 years before it stopped.
- 25 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Aegera Therapeutics
- Sponsor type
- Industry
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell
- Interventions
- AEG35156 antisense IV infusion
- Participants
- 25
- Sites
- 7
- Countries
- Canada, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.